Estrogen based therapy are expected to hold 53% of the market share in 2023 for Atrophic vaginitis treatment market. Rising Prevalence of Atrophic Vaginitis Cases in Menopausal Women Across the Globe is Driving Atrophic Vaginitis Treatment Market Revenue Growth.
NEWARK, Del, March 28, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Atrophic vaginitis treatment market is expected to grow at a value of 8% CAGR, according to Future Market Insights. By the year 2033, the global market for Atrophic vaginitis treatment is expected to rise up to a market valuation of US$ 6 Billion. The atrophic vaginitis treatment market is expected to grow significantly in the coming years due to the increasing prevalence of the condition.
According to a report published by the National Institutes of Health, approximately 50% of women experience vaginal dryness and discomfort after menopause, and around 10-40% of these women experience atrophic vaginitis. This translates to millions of women who are in need of proper treatment.
The market offers various treatment options, including hormone replacement therapy, topical estrogen creams, and vaginal moisturizers. Hormone replacement therapy is one of the most effective treatments for atrophic vaginitis. It involves taking hormones to replace the estrogen that the body is no longer producing. This treatment has been proven to reduce symptoms such as vaginal dryness, itching, and painful intercourse.
Request a Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16831
Topical estrogen creams are another popular treatment option. These creams are applied directly to the vagina and help to restore the natural moisture and elasticity of the vaginal tissues. They are easy to use and have been shown to be effective in relieving symptoms. Thus, with the availability of effective treatments, the atrophic vaginitis market is expected to grow in the upcoming years.
Key Takeaways from the Market Study
The global Atrophic vaginitis treatment market is expected to grow with an 8% CAGR during 2023 to 2033.
By therapy type, Estrogen based therapy are expected to hold 53% of the market share in 2023 for Atrophic vaginitis treatment market.
North America is expected to possess 48% market share for Atrophic vaginitis treatment market in 2023.
Europe Atrophic vaginitis treatment market size is expected to possess 43% market share in 2023.
“The atrophic vaginitis treatment market is revolutionizing women's health by providing effective solutions to a common condition that affects millions of women worldwide. With the increasing prevalence of the condition, the market is expected to grow significantly in the coming years. Despite the challenges faced by the industry” states an FMI analyst
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
Shionogi is a pharmaceutical company that has developed a treatment for atrophic vaginitis called Intrarosa (prasterone). Intrarosa is a vaginal insert that contains the hormone dehydroepiandrosterone (DHEA), which is converted into estrogen in the body.
Bayer HealthCare Pharmaceuticals Inc, a key player in the atrophic vaginitis treatment market is focusing on developing treatments for the ailment by researching and investing in developing therapies.
Want your report customized? Speak to an analyst and personalize your report according to your needs @ https://www.futuremarketinsights.com/ask-question/rep-gb-16831
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Atrophic vaginitis treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Diagnosis (Pelvic exam, Urine test, Acid balance test) Treatment (Vaginal moisturizers and Water-based lubricants) Therapy Type (Estrogen based drugs and Non-estrogen based drugs) Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Key Segments Profiled in the Atrophic Vaginitis Treatment Industry Survey
Acid balance test
Estrogen based drugs
Non-estrogen based drugs
Browse Full Report with Facts and Figures @ https://www.futuremarketinsights.com/reports/atrophic-vaginitis-treatment-market
Table of Content
1. Executive Summary | Atrophic Vaginitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
Click here to buy complete report @ https://www.futuremarketinsights.com/checkout/16831
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
Critical Care Patient Monitoring Products Market Size: The critical care patient monitoring products market is expected to grow at a CAGR of 8.6%.
Non Fusion Spinal Devices Market Share: The non fusion spinal devices market is expected to be valued at US$ 4.37 billion in 2023. The market is projected to rise at a CAGR of 4.8% from 2023 to 2033, to attain a market value of US$ 6.99 billion by 2033.
Immunochemistry Products Market Demand: The immunochemistry products market is anticipated to record a CAGR of 7.25% during the forecast period, up from US$ 2.08 Bn in 2021 to reach a valuation of US$ 4.5 Bn by 2032.
Immunochemistry Analyzer Market Analysis: The immunochemistry analyzer market is expected to register a CAGR of 16% during the forecast period, up from US$ 14.2 Bn in 2021, to reach a valuation of US$ 72.69 Bn by 2032.
Infant Care And Baby Care Equipment Market Forecast: The infant care and baby care equipment market is expected to increase at a CAGR of 5.7% from an estimated USD 6.4 billion in 2018 to USD 8.4 billion by 2023.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA